Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Melphalan Flufenamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.51 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.51 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.51 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.51 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.51 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.51 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.51 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.51 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.51 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.38 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Melphalan Flufenamide SCHEMBL20208719 | 0.99 | LMNA (0.53) | LMNACYP3A4SMN1; SMN2KMT2AALDH1A1 | |
| Melphalan Flufenamide SCHEMBL24101233 | 0.99 | LMNA (0.53) | LMNACYP3A4SMN1; SMN2KMT2AALDH1A1 | |
| Melphalan Flufenamide SCHEMBL18239898 | 0.99 | LMNA (0.53) | LMNACYP3A4SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL24251989 | 0.92 | LMNA (0.47) | LMNACYP3A4SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL6838403 | 0.91 | LMNA (0.47) | LMNACYP3A4SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL10653540 | 0.91 | LMNA (0.47) | LMNACYP3A4SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL24100557 | 0.90 | LMNA (0.44) | LMNACYP3A4SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL25022336 | 0.90 | LMNA (0.43) | LMNACYP3A4SMN1; SMN2KMT2AALDH1A1 | |
| Melphalan Flufenamide SCHEMBL29409225 | 0.89 | LMNA (0.48) | LMNACYP3A4SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL22240387 | 0.88 | LMNA (0.51) | LMNACYP3A4SMN1; SMN2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363450-A1 | ANTI-TIGIT AND ANTI-PVRIG IN MONOTHERAPY AND COMBINATION TREATMENTS | Compugen Ltd. (IL) | 2024-05-08 | — | — | EP | claimed |
| WO-2023275621-A1 | ANTI-TIGIT AND ANTI-PVRIG IN MONOTHERAPY AND COMBINATION TREATMENTS | COMPUGEN LTD. (IL) | 2023-01-05 | — | — | WO | claimed |
| US-20220047507-A1 | MELFLUFEN DOSAGE REGIMENS FOR CANCER | ONCOPEPTIDES AB (SE) | 2022-02-17 | — | — | US | claimed |
| US-12624004-B2 | Opioid receptor agonist, preparation method therefor and pharmaceutical use thereof | FUDAN UNIVERSITY (CN) | 2026-05-12 | — | — | US | disclosed |
| US-12558337-B2 | Formulations comprising melflufen | ONCOPEPTIDES INNOVATION AB (SE) | 2026-02-24 | — | — | US | disclosed |
| US-20260049060-A1 | TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS | NATIONAL HEALTH RES INST (TW) | 2026-02-19 | — | — | US | disclosed |
| US-20260021067-A1 | TREATMENT OF AL AMYLOIDOSIS WITH MELFLUFEN | ONCOPEPTIDES AB (SE) | 2026-01-22 | — | — | US | disclosed |
| US-20250382364-A1 | ANTI-TIGIT AND ANTI-PVRIG IN MONOTHERAPY AND COMBINATION TREATMENTS | COMPUGEN LTD (IL) | 2025-12-18 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12396975-B2 | Treatment of al amyloidosis with melflufen | ONCOPEPTIDES AB (SE) | 2025-08-26 | — | — | US | disclosed |
| EP-4588524-A2 | ANTI-TIGIT AND ANTI-PVRIG IN MONOTHERAPY AND COMBINATION TREATMENTS | Compugen Ltd. (IL) | 2025-07-23 | — | — | EP | disclosed |
| CN-114702564-A | Exosome peptide and preparation method and application thereof | 江苏省人民医院（南京医科大学第一附属医院） | 2022-07-05 | — | — | CN | disclosed |
| US-20220193019-A1 | TREATMENT OF AL AMYLOIDOSIS WITH MELFLUFEN | ONCOPEPTIDES AB (SE) | 2022-06-23 | — | — | US | disclosed |
| US-20220184021-A1 | NOVEL FORMULATIONS COMPRISING MELFLUFEN | ONCOPEPTIDES AB (SE) | 2022-06-16 | — | — | US | disclosed |
| US-11344622-B2 | Lyophilized preparation of cytotoxic dipeptides | ONCOPEPTIDES AB (SE) | 2022-05-31 | — | — | US | disclosed |
| EP-3956032-A1 | NOVEL FORMULATIONS COMPRISING MELFLUFEN | Oncopeptides AB (SE) | 2022-02-23 | — | — | EP | disclosed |
| US-20220047507-A1 | MELFLUFEN DOSAGE REGIMENS FOR CANCER | ONCOPEPTIDES AB (SE) | 2022-02-17 | — | — | US | disclosed |
| CN-114040798-A | Novel formulations comprising meflufen | 肿瘤多肽有限公司 | 2022-02-11 | — | — | CN | disclosed |
| EP-3946309-A1 | TREATMENT OF AL AMYLOIDOSIS WITH MELFLUFEN | Oncopeptides AB (SE) | 2022-02-09 | — | — | EP | disclosed |
| CN-114025753-A | Treatment of AL amyloidosis with meflufen | 肿瘤多肽有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049060-A1 | TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS | OPRK1, OPRD1, OPRM1 | CHRM2 910/4885ADRA2A 216/4885CHRM1 739/4885 |
| US-12396975-B2 | Treatment of al amyloidosis with melflufen | MME, TTR, MLLT1 | CHRM2 4156/4885ADRA2A 1942/4885CHRM1 4649/4885 |
| US-20220193019-A1 | TREATMENT OF AL AMYLOIDOSIS WITH MELFLUFEN | MME, TTR, MLLT1 | CHRM2 4156/4885ADRA2A 1942/4885CHRM1 4649/4885 |
| US-20220047507-A1 | MELFLUFEN DOSAGE REGIMENS FOR CANCER | MME, SLC43A1, SLC7A5 | CHRM2 3878/4885ADRA2A 2820/4885CHRM1 4270/4885 |
| US-12558337-B2 | Formulations comprising melflufen | PHF8, EZH2, PHF2 | CHRM2 2676/4885ADRA2A 3247/4885CHRM1 3861/4885 |
| US-12624004-B2 | Opioid receptor agonist, preparation method therefor and pharmaceutical use thereof | OPRM1, OPRD1, OPRK1 | CHRM2 619/4885ADRA2A 164/4885CHRM1 527/4885 |
| US-20260021067-A1 | TREATMENT OF AL AMYLOIDOSIS WITH MELFLUFEN | MME, MYOF, TTR | CHRM2 3382/4885ADRA2A 2944/4885CHRM1 4090/4885 |
| US-11344622-B2 | Lyophilized preparation of cytotoxic dipeptides | TREH, SORD, SI | CHRM2 4189/4885ADRA2A 3741/4885CHRM1 4515/4885 |
| US-20220184021-A1 | NOVEL FORMULATIONS COMPRISING MELFLUFEN | F12, FGF2, MC3R | CHRM2 900/4885ADRA2A 1638/4885CHRM1 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.